Serum Institute of India to price Covid-19 vaccine at USD 3 per dose

SII to produce 100 mn doses of Covishield for India and other low- and middle-income nations

Serum Institute of India to price Covid-19 vaccine at USD 3 per dose

Photo for representational purpose only.

World’s leading vaccine maker Serum Institute of India on Friday said it would produce up to

100 million Covid-19 vaccine doses for India and low- and middle-income countries as early

as 2021.

The institute in a statement said it would price each dose of the vaccine for USD 3 which

roughly translates into Indian Rupees 225.

SII issued the statement after entering into what it called a new landmark collaboration between

the SII, GAVI (Global Alliance for Vaccines) and Bill and Melinda Gates Foundation.

SII to get $150 mn from Gates Foundation

Under the arrangement the Bill andMelinda Gates Goundation via its strategic investment fund

will provide at-risk funding of USD 150 million to GAVI which will be used to support the SII

to manufacture the potential vaccine candidates.

“Vaccines will be priced at maximum USD 3 per dose and made available to the 92 countries

included in GAVI’s COVAX Advance Market Commitment,” Adar Poonawala-led SII said in

a statement.

Pune based Serum Institute has partnered with Oxford University and British Swedish Pharma

firm Astra Zeneca to mass produce the frontrunner COVID 19 vaccine Covishield which has

entered phase 3 clinical trials in some countries after showing safety and immune response in

phase 1 and 2 studies in the UK.

Indian Drug controller has also permitted SII to undertake phase 2 and 3 human trials on

Covishield in India.

https://www.tribuneindia.com/news/health/serum-institute-of-india-to-price-covid-19-

vaccine-at-usd-3-per-dose-123458